News | October 25, 2021
Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The order strengthens the company’s position in the East African market
Subscribe To Our Newsletter & Stay Updated
